Developmental and Epileptic Encephalopathies Diagnosed Via Long-read Genome Sequencing

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 18
SponsorUniversity Hospital, Strasbourg, France

About this trial

This study focuses on children with Developmental and Epileptic Encephalopathy (DEE), a severe form of epilepsy that often has a genetic origin. Currently, standard diagnostic tools-known as short-read genome sequencing-fail to provide a diagnosis for over 50% of affected patients because they cannot detect certain complex DNA abnormalities.

The purpose of this study is to evaluate the effectiveness of a newer, more advanced technology called Long-read Genome Sequencing (lrWGS). Unlike traditional methods, this technology analyzes very long fragments of DNA, allowing researchers to identify genetic errors that were previously "invisible."

The study aims to answer whether Long-read Sequencing can successfully identify the genetic cause of epilepsy in patients who have already received a negative result from standard testing. By finding these missing answers, the research seeks to enable personalized medical treatments, improve genetic counseling for families, and advance our understanding of how these complex neurological conditions develop.

Eligibility criteria

Qualifiers

Age < 18 years.

Diagnosis of Developmental and Epileptic Encephalopathy (DEE) according to 2022 ILAE criteria (severe epilepsy, encephalopathic EEG, multiple drug-resistant seizures, and neurodevelopmental disorder).

Brain MRI without markers of perinatal anoxia.

Negative molecular diagnosis after short-read Whole Genome Sequencing (srWGS) via the French Genomic Medicine Plan 2025 (AURAGEN).

Disqualifiers

Brain MRI findings in favor of perinatal cerebral anoxia.

Intercurrent diseases preventing the completion of protocol examinations.

Subject currently in an exclusion period from another study.

Inability to receive or understand informed information (e.g., life-threatening emergency).

Trial design

Treatments tested in this trial

  • Long-read Whole Genome Sequencing (lrWGS)

Treatment groups

20 Participants
are divided into 1 treatment group

Sponsors and collaborators

University Hospital, Strasbourg, France

Lead sponsor

IGBMC

Collaborator

Laboratoire de diagnostic génétique - NHC

Collaborator

Groupe Méthode en Recherche Clinique (GMRC)

Collaborator

Bio-informatique médicale appliquée au diagnostic (UF7363) - NHC

Collaborator